Should I buy or sell Neuronetics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STIM shares. View STIM analyst ratings or view top-rated stocks .

What is Neuronetics' stock price target for 2024?

2 analysts have issued 1-year price objectives for Neuronetics' shares. Their STIM share price targets range from $7.00 to $12.00. On average, they anticipate the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 402.6% from the stock's current price. View analysts price targets for STIM or view top-rated stocks among Wall Street analysts .

How have STIM shares performed in 2023?

Neuronetics' stock was trading at $6.87 at the start of the year. Since then, STIM shares have decreased by 72.5% and is now trading at $1.89. View the best growth stocks for 2023 here .

When is Neuronetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024. View our STIM earnings forecast .

How were Neuronetics' earnings last quarter?

Neuronetics, Inc. (NASDAQ:STIM) posted its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.03. The business earned $17.88 million during the quarter, compared to the consensus estimate of $17.66 million. Neuronetics had a negative trailing twelve-month return on equity of 70.12% and a negative net margin of 47.81%.

What guidance has Neuronetics issued on next quarter's earnings?

Neuronetics updated its fourth quarter 2023 earnings guidance on Tuesday, November, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $19.00 million-$21.00 million, compared to the consensus revenue estimate of $19.76 million.

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX) , Inovio Pharmaceuticals (INO) , Novavax (NVAX) , Gilead Sciences (GILD) , Onconova Therapeutics (ONTX) , Pfizer (PFE) , Tonix Pharmaceuticals (TNXP) , Vaxart (VXRT) and Acasti Pharma (ACST) .

When did Neuronetics IPO?

(STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Who are Neuronetics' major shareholders?

Neuronetics' stock is owned by many different institutional and retail investors. Top institutional investors include Cannell Capital LLC (9.80%), Kent Lake Capital LLC (8.05%), First Eagle Investment Management LLC (2.69%), Acadian Asset Management LLC (1.28%), Millrace Asset Group Inc. (0.82%) and Blair William & Co. IL (0.32%). Insiders that own company stock include Bruce Joseph Shook , Cannell Capital Llc, Gregory Harper , Keith J Sullivan , Paul Liberman, Robert Cascella , Sheryl L Conley , Stephen Furlong and William Andrew Macan . View institutional ownership trends .

How do I buy shares of Neuronetics?

Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

Neuronetics Stock Price, News & Analysis (NASDAQ:STIM)

$1.89

-0.06 (-3.08%)

(As of 12/6/2023 ET)

Compare

Today's Range: $1.87
▼
$1.99
50-Day Range: $1.05
▼
$2.21
52-Week Range: $1.03
▼
$6.95

Volume: 46,913 shs
Average Volume: 163,902 shs
Market Capitalization: $54.68 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.50

Neuronetics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 402.6% Upside
$9.50 Price Target
Short Interest: Bearish
1.27% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.68
Based on 2 Articles This Week
Insider Trading: Selling Shares
$3,443 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.13) to ($0.91) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

221st out of 957 stocks

Surgical & Medical Instruments Industry

26th out of 78 stocks

3.5

Analyst's Opinion

Consensus Rating
Neuronetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.50, Neuronetics has a forecasted upside of 402.6% from its current price of $1.89.
Amount of Analyst Coverage
Neuronetics has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
1.27% of the outstanding shares of Neuronetics have been sold short.
Short Interest Ratio / Days to Cover
Neuronetics has a short interest ratio ("days to cover") of 4.8.
Change versus previous month
Short interest in Neuronetics has recently increased by 0.88%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Neuronetics does not currently pay a dividend.
Dividend Growth
Neuronetics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for STIM.

3.7

News and Social Media Coverage

News Sentiment
Neuronetics has a news sentiment score of 1.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Neuronetics this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for STIM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
2 people have added Neuronetics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Neuronetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,443.00 in company stock.
Percentage Held by Insiders
Only 5.20% of the stock of Neuronetics is held by insiders.
Percentage Held by Institutions
62.23% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Neuronetics are expected to grow in the coming year, from ($1.13) to ($0.91) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Neuronetics is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Neuronetics is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Neuronetics has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Neuronetics Stock (NASDAQ:STIM)

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

STIM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

STIM Stock News Headlines

December 4, 2023 | finance.yahoo.com

NeuroStar TMS Receives Expanded Regulatory Approval in Japan

December 2, 2023 | finance.yahoo.com

Investors in Neuronetics (NASDAQ:STIM) from five years ago are still down 90%, even after 40% gain this past week

December 7, 2023 | Edge On The Street (Ad)

Americans Now Favor Gold Over Stocks as an Investment Vehicle

Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.

November 15, 2023 | finance.yahoo.com

Neuronetics to Present at the 35th Annual Piper Sandler Healthcare Conference

November 13, 2023 | finanznachrichten.de

Neuronetics: NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements

November 13, 2023 | finance.yahoo.com

NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements

November 10, 2023 | benzinga.com

Deep Brain Stimulation Devices Market to Hit $2,508.5 Million by 2030, Rising at 9.8% CAGR | Coherent Market Insights

November 9, 2023 | markets.businessinsider.com

Positive Q3 Results and Commercial Initiatives Drive Plovanic’s Buy Rating on Neuronetics (STIM)

December 7, 2023 | Financial Alphas (Ad)

Lithium Discovery So BIG You Can't Miss it, Even From Space

With the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!

November 9, 2023 | finance.yahoo.com

Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage

November 8, 2023 | finance.yahoo.com

Neuronetics, Inc. (NASDAQ:STIM) Q3 2023 Earnings Call Transcript

November 7, 2023 | finance.yahoo.com

Neuronetics Reports Third Quarter 2023 Financial and Operating Results

November 7, 2023 | finance.yahoo.com

Neuronetics Inc (STIM) Reports 8% Revenue Growth in Q3 2023

October 24, 2023 | finance.yahoo.com

Neuronetics to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call

October 16, 2023 | finance.yahoo.com

Brain Stimulation Highlights Best Practices for Optimal TMS Treatment Outcomes

October 3, 2023 | finance.yahoo.com

Neuronetics Draws Down Remaining $22.5 Million Available Under Credit Facility

September 21, 2023 | benzinga.com

Board Member of Neuronetics Purchased $51K In Stock

September 12, 2023 | finance.yahoo.com

In Recognition of Suicide Prevention Month, NeuroStar Voices Portal Amplifies Stories of Real People Beating Depression

September 6, 2023 | msn.com

Neuronetics: Large Losses May Be Repelling Investors

August 24, 2023 | 247wallst.com

Cannell Capital Now Owns 8.45% of Neuronetics

August 19, 2023 | finance.yahoo.com

Cannell Capital LLC Reduces Stake in Neuronetics Inc

August 14, 2023 | finance.yahoo.com

Neuronetics Revolutionizes Patient Communication and Provider Support Through Its Exclusive TrakStar® Platform

August 11, 2023 | finance.yahoo.com

Neuronetics (STIM) Upgraded to Buy: What Does It Mean for the Stock?

August 9, 2023 | markets.businessinsider.com

Neuronetics (STIM) Receives a Buy from JMP Securities

August 8, 2023 | finance.yahoo.com

Neuronetics Reports Record Second Quarter 2023 Financial and Operating Results

July 25, 2023 | finance.yahoo.com

Neuronetics to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call

July 22, 2023 | ca.finance.yahoo.com

STIM - Neuronetics, Inc.

See More Headlines

Receive STIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/05/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:STIM
CUSIP: N/A
CIK: 1227636
Web: www.neurostar.com
Phone: (610) 640-4202
Fax: 610-640-4206
Employees: 211
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.50
High Stock Price Target: $12.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +402.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.18)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-37,160,000.00
Net Margins: -47.81%
Pretax Margin: -47.81%
Return on Equity: -70.12%
Return on Assets: -31.99%

Debt

Debt-to-Equity Ratio: 0.97
Current Ratio: 4.63
Quick Ratio: 4.00

Sales & Book Value

Annual Sales: $65.21 million
Price / Sales: 0.84
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.10 per share
Price / Book: 0.90

Miscellaneous

Outstanding Shares: 28,930,000
Free Float: 27,428,000
Market Cap: $54.68 million
Optionable: Not Optionable
Beta: 2.03

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Keith J. Sullivan (Age 65)
President, CEO & Director
Comp: $1.53M
Mr. Stephen J. Furlong M.S. (Age 59)
Executive VP, CFO & Treasurer
Comp: $787.87k
Mr. W. Andrew Macan (Age 50)
Executive VP, GC, Chief Compliance Officer & Corporate Secretary
Comp: $646.55k
Mr. Rusty Page
Senior VP of Operations & Quality
Ms. Lisa Metzner-Rosas
Senior VP & Chief Marketing Officer
Ms. Kara Thornton
Senior Vice President of Human Resources
Ms. Sara Grubbs
Senior VP & Chief Revenue Officer
Mr. Rick Grubbs
Senior Vice President of National Accounts
Mr. Cory S. Anderson
Senior Vice President of R&D and Clinical

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

STIM Stock Analysis - Frequently Asked Questions

Should I buy or sell Neuronetics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STIM shares.
View STIM analyst ratings or view top-rated stocks.
What is Neuronetics' stock price target for 2024?: 2 analysts have issued 1-year price objectives for Neuronetics' shares. Their STIM share price targets range from $7.00 to $12.00. On average, they anticipate the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 402.6% from the stock's current price.
View analysts price targets for STIM or view top-rated stocks among Wall Street analysts.
How have STIM shares performed in 2023?: Neuronetics' stock was trading at $6.87 at the start of the year. Since then, STIM shares have decreased by 72.5% and is now trading at $1.89.
View the best growth stocks for 2023 here.
When is Neuronetics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our STIM earnings forecast.
How were Neuronetics' earnings last quarter?: Neuronetics, Inc. (NASDAQ:STIM) posted its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.03. The business earned $17.88 million during the quarter, compared to the consensus estimate of $17.66 million. Neuronetics had a negative trailing twelve-month return on equity of 70.12% and a negative net margin of 47.81%.
What guidance has Neuronetics issued on next quarter's earnings?: Neuronetics updated its fourth quarter 2023 earnings guidance on Tuesday, November, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $19.00 million-$21.00 million, compared to the consensus revenue estimate of $19.76 million.

What other stocks do shareholders of Neuronetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).
When did Neuronetics IPO?: (STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.
Who are Neuronetics' major shareholders?: Neuronetics' stock is owned by many different institutional and retail investors. Top institutional investors include Cannell Capital LLC (9.80%), Kent Lake Capital LLC (8.05%), First Eagle Investment Management LLC (2.69%), Acadian Asset Management LLC (1.28%), Millrace Asset Group Inc. (0.82%) and Blair William & Co. IL (0.32%). Insiders that own company stock include Bruce Joseph Shook, Cannell Capital Llc, Gregory Harper, Keith J Sullivan, Paul Liberman, Robert Cascella, Sheryl L Conley, Stephen Furlong and William Andrew Macan.
View institutional ownership trends.
How do I buy shares of Neuronetics?: Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:STIM) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial